On last night’s @60Minutes episode, @NIH director Francis Collins, MD, PhD, spoke about #WashUMed psychiatrists Eric Lenze, MD, and Angela Reiersen, MD, and their successful study using fluvoxamine to treat COVID patients. https://t.co/1gk6Rkydea
— Washington U. Med (@WUSTLmed) March 8, 2021
When child psychiatrist Dr. Angela Reiersen had COVID symptoms last March, she remembered a study in which the antidepressant drug fluvoxamine stopped a runaway immune response in mice. It’s believed that a similar immune response occurs in COVID patients. https://t.co/nxJtPIfNrQ pic.twitter.com/lFfsB05G9D
— 60 Minutes (@60Minutes) March 8, 2021
“Of the 80 people who received fluvoxamine, none…deteriorated, vs. 8% of the people who got placebo,” says Dr. Lenze who ran a small study on the effectiveness of the antidepressant fluvoxamine in preventing COVID patients from deteriorating. https://t.co/k6ye0dCtZf pic.twitter.com/GBdM9tRlgf
— 60 Minutes (@60Minutes) March 8, 2021